Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?

Clinical Cardiology

Volumn 30, Issue 9, 2007, Pages 469-474

  Li, N A ^a   Li, Yishi ^a   Wang, Fang ^a   Jiang, Wen ^a   Huang, Jie ^a   Xu, Zhimin ^a   Hua, Lu ^a   Hua, Congxiao ^a   Huang, Yan ^a   Wu, Ying ^a   Li, Feiou ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Adrenergic beta antagonists; Brain; Congestive; Heart failure; Natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RATE; HUMAN; MALE; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; BIOLOGICAL MARKERS; BISOPROLOL; CARBAZOLES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROPANOLAMINES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 34548809695     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20150     Document Type: Article

References (20)

1. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-585
2. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M: Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-832
3. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, et al.: Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): a new marker of cardiac impairment. Clin Endocrinol 1997;47:287-296
4. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA: The amino-terminal portion of pro-brain natriuretic peptide (proBNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175-1183
5. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, et al.: Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004;42:37-44
6. Clerico A, Emdin M: Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004;50:33-50
7. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA: N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-1743
8. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, et al.: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from Carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001;37:1781-1787
9. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls GA, et al.: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130
10. Tanaka M, Ishizaka Y, Ishiyama Y, Kato J, Kida O, et al.: Chronic effect of beta-adrenoceptor blockade on plasma levels of brain natriuretic peptide during exercise in essential hypertension. Hypertens Res 1996;19:239-245
11. Sanderson JE, Chan WW, Hung YT, Chan SK, Shun IO, et al.: Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995;7:502-507
12. Marie PY, Mertes PM, Hassan-Sebbag N, de Talence N, Djaballah K, et al.: Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Coll Cardiol 2004; 43:353-359
13. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, et al.: Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005;23:1083-1090
14. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, et al.: Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006;113:977-985
15. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, et al.: NT-proBNP in severe chronic heart filure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004;6:343-350
16. Jourdain P, Funck F, Willemard C, Bellorini M, Guillard N, et al.: BNP and betablocker therapy in chronic heart failure. Eur Heart J 2000;21(suppl):403, Abstract
17. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, et al.: The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
18. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure(MERIT-HF). Lancet 1999; 353:2001-2007
19. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II(CIBIS-II): a randomized trial. Lancet 1999;353:9-13
20. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, et al.: Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998;32:1839-1844